耐药和交叉耐药乙型肝炎病毒突变体的适应性与传染性：为何以及如何进行研究？
Fitness and infectivity of drug-resistant and cross-resistant hepatitis B virus mutants: why and how is it studied?
作者信息
Durantel David
机构信息
INSERM, U871, Lyon, France.
出版信息
Antivir Ther. 2010;15(3 Pt B):521-7. doi: 10.3851/IMP1551.
Abstract
The emergence of hepatitis B virus (HBV) drug-resistant (and multidrug-resistant) strains during long-term therapy with nucleoside/nucleotide analogues is associated with treatment failure and, therefore, represents a clinical challenge. For clinicians, the close monitoring and management of resistance has become a key issue in clinical practice. For HBV virologists, the understanding of the mechanism of emergence of specific mutant strains in the viral quasispecies during treatment is also an important issue. If a particular viral strain can emerge in the quasispecies within a particular environment, it is probably because its fitness is superior to other strains. The present review focuses on viral fitness as well as viral infectivity, and in particular on technical means that are available to study this viral fitness in vitro and in animal models.
摘要
在核苷/核苷酸类似物长期治疗期间，乙型肝炎病毒（HBV）耐药（及多重耐药）毒株的出现与治疗失败相关，因此是一项临床挑战。对临床医生而言，耐药性的密切监测与管理已成为临床实践中的关键问题。对HBV病毒学家来说，了解治疗期间病毒准种中特定突变毒株的出现机制也是一个重要问题。如果特定病毒毒株能在特定环境下的准种中出现，很可能是因为其适应性优于其他毒株。本综述聚焦于病毒适应性以及病毒感染性，尤其关注可用于在体外和动物模型中研究这种病毒适应性的技术手段。
相似文献
1
Fitness and infectivity of drug-resistant and cross-resistant hepatitis B virus mutants: why and how is it studied?耐药和交叉耐药乙型肝炎病毒突变体的适应性与传染性：为何以及如何进行研究？
Antivir Ther. 2010;15(3 Pt B):521-7. doi: 10.3851/IMP1551.
2
Molecular cloning and phenotypic analysis of drug-resistance mutants with relevant S-region variants of HBV for a patient during 189-month anti-HBV treatment.对一名接受189个月抗乙肝病毒治疗患者的乙肝病毒相关S区变异耐药突变体进行分子克隆及表型分析
Antivir Ther. 2019;24(4):237-246. doi: 10.3851/IMP3305.
3
Evaluation of novel strategies to combat hepatitis B virus targetting wild-type and drug-resistant mutants in experimental models.在实验模型中评估针对野生型和耐药突变体的新型抗乙型肝炎病毒策略。
Antivir Chem Chemother. 2001;12 Suppl 1:131-42.
4
Impact of hepatitis B e antigen-suppressing mutations on the replication efficiency of entecavir-resistant hepatitis B virus strains.乙型肝炎 e 抗原抑制突变对恩替卡韦耐药乙型肝炎病毒株复制效率的影响。
J Viral Hepat. 2011 Nov;18(11):804-14. doi: 10.1111/j.1365-2893.2010.01378.x. Epub 2010 Sep 30.
5
In vitro models for studying hepatitis B virus drug resistance.用于研究乙型肝炎病毒耐药性的体外模型。
Semin Liver Dis. 2006 May;26(2):171-80. doi: 10.1055/s-2006-939759.
6
Hepatitis B virus mutations associated with antiviral therapy.与抗病毒治疗相关的乙型肝炎病毒突变
J Med Virol. 2006;78 Suppl 1:S52-5. doi: 10.1002/jmv.20608.
7
In vitro susceptibility of lamivudine-resistant hepatitis B virus to adefovir and tenofovir.拉米夫定耐药乙型肝炎病毒对阿德福韦和替诺福韦的体外敏感性
Antivir Ther. 2004 Jun;9(3):353-63.
8
Pathobiology of HBV mutants and clinical impact for treatment monitoring.乙肝病毒突变体的病理生物学及其对治疗监测的临床影响
Expert Rev Anti Infect Ther. 2009 Apr;7(3):309-20. doi: 10.1586/eri.09.10.
9
Hepatitis B virus escape mutants induced by antiviral therapy.抗病毒治疗诱导的乙型肝炎病毒逃逸突变体
J Antimicrob Chemother. 2008 Apr;61(4):766-8. doi: 10.1093/jac/dkn014. Epub 2008 Jan 24.
10
Resistance of hepatitis B virus to antiviral drugs: current aspects and directions for future investigation.乙型肝炎病毒对抗病毒药物的耐药性：当前情况及未来研究方向
Antivir Chem Chemother. 2001 Jan;12(1):1-35. doi: 10.1177/095632020101200101.
引用本文的文献
1
Inhibition of Hepatitis B Virus Replication by a Novel GalNAc-siRNA In Vivo and In Vitro.新型N-乙酰半乳糖胺-小干扰RNA在体内外对乙型肝炎病毒复制的抑制作用
ACS Omega. 2025 Jan 3;10(1):484-497. doi: 10.1021/acsomega.4c06840. eCollection 2025 Jan 14.
2
Establishment of stable cell lines in which the HBV genome replicates episomally for evaluation of antivirals.建立HBV基因组以附加体形式复制的稳定细胞系用于抗病毒药物评估。
Arch Med Sci. 2018 Nov 20;16(2):407-413. doi: 10.5114/aoms.2018.79712. eCollection 2020.
3
Novel fluoronucleoside analog NCC inhibits lamivudine-resistant hepatitis B virus in a hepatocyte model.新型氟核苷类似物 NCC 在肝细胞模型中抑制拉米夫定耐药的乙型肝炎病毒。
Braz J Infect Dis. 2018 Nov-Dec;22(6):477-486. doi: 10.1016/j.bjid.2018.11.005. Epub 2018 Dec 23.
4
Clinical features of treatment-naive patients with hepatitis B virus infection: A community-based survey from high- and intermediate-hepatitis B endemicity regions in Southeast China.未经治疗的乙型肝炎病毒感染患者的临床特征：来自中国东南部乙型肝炎高流行和中流行地区的一项基于社区的调查。
Medicine (Baltimore). 2017 Apr;96(16):e6660. doi: 10.1097/MD.0000000000006660.
5
Increased replicative fitness can lead to decreased drug sensitivity of hepatitis C virus.复制适应性增加可导致丙型肝炎病毒对药物的敏感性降低。
J Virol. 2014 Oct;88(20):12098-111. doi: 10.1128/JVI.01860-14. Epub 2014 Aug 13.
6
A description of the hepatitis B virus genomic background in a high-prevalence area in China.中国高发地区乙型肝炎病毒基因组背景描述。
Virol J. 2014 May 31;11:101. doi: 10.1186/1743-422X-11-101.
7
Computational evolutionary analysis of the overlapped surface (S) and polymerase (P) region in hepatitis B virus indicates the spacer domain in P is crucial for survival.对乙型肝炎病毒重叠表面（S）和聚合酶（P）区的计算进化分析表明，P 区中的间隔区对于生存至关重要。
PLoS One. 2013;8(4):e60098. doi: 10.1371/journal.pone.0060098. Epub 2013 Apr 5.
8
Clonal evolution of hepatitis B virus polymerase gene mutations during lamivudine-adefovir combination treatment.拉米夫定-阿德福韦酯联合治疗期间乙型肝炎病毒聚合酶基因突变的克隆进化。
World J Gastroenterol. 2012 Nov 28;18(44):6437-46; discussion p.6445. doi: 10.3748/wjg.v18.i44.6437.
9
Viral quasispecies evolution.病毒准种进化。
Microbiol Mol Biol Rev. 2012 Jun;76(2):159-216. doi: 10.1128/MMBR.05023-11.
本文引用的文献
1
A function essential to viral entry underlies the hepatitis B virus "a" determinant.乙肝病毒“a”决定簇的基础是病毒进入所必需的一种功能。
J Virol. 2009 Sep;83(18):9321-8. doi: 10.1128/JVI.00678-09. Epub 2009 Jul 1.
2
Efficacy of hepatitis B vaccine against antiviral drug-resistant hepatitis B virus mutants in the chimpanzee model.乙肝疫苗对黑猩猩模型中抗病毒药物耐药性乙肝病毒突变体的疗效。
Hepatology. 2009 May;49(5):1483-91. doi: 10.1002/hep.22796.
3
Management and prevention of drug resistance in chronic hepatitis B.慢性乙型肝炎耐药性的管理与预防
Liver Int. 2009 Jan;29 Suppl 1:108-15. doi: 10.1111/j.1478-3231.2008.01939.x.
4
Direct cytopathic effects of particular hepatitis B virus genotypes in severe combined immunodeficiency transgenic with urokinase-type plasminogen activator mouse with human hepatocytes.携带人肝细胞的尿激酶型纤溶酶原激活剂转基因严重联合免疫缺陷小鼠中特定乙型肝炎病毒基因型的直接细胞病变效应
Gastroenterology. 2009 Feb;136(2):652-62.e3. doi: 10.1053/j.gastro.2008.10.048. Epub 2008 Oct 29.
5
In vitro characterization of viral fitness of therapy-resistant hepatitis B variants.治疗耐药型乙型肝炎变异株病毒适应性的体外特征分析
Gastroenterology. 2009 Jan;136(1):168-176.e2. doi: 10.1053/j.gastro.2008.09.068. Epub 2008 Oct 7.
6
Hepatitis B virus infection.乙型肝炎病毒感染
N Engl J Med. 2008 Oct 2;359(14):1486-500. doi: 10.1056/NEJMra0801644.
7
The human liver-uPA-SCID mouse: a model for the evaluation of antiviral compounds against HBV and HCV.人肝-uPA-SCID小鼠：一种用于评估抗HBV和HCV抗病毒化合物的模型。
Antiviral Res. 2008 Dec;80(3):231-8. doi: 10.1016/j.antiviral.2008.07.006. Epub 2008 Aug 14.
8
Initiation of hepatitis B virus genome replication and production of infectious virus following delivery in HepG2 cells by novel recombinant baculovirus vector.新型重组杆状病毒载体在HepG2细胞中递送后启动乙型肝炎病毒基因组复制并产生感染性病毒。
J Gen Virol. 2008 Aug;89(Pt 8):1819-1828. doi: 10.1099/vir.0.83659-0.
9
10
The antiviral drug selected hepatitis B virus rtA181T/sW172* mutant has a dominant negative secretion defect and alters the typical profile of viral rebound.所选的抗乙肝病毒药物对乙肝病毒rtA181T/sW172*突变体具有显性负性分泌缺陷，并改变了病毒反弹的典型模式。
Hepatology. 2008 Jul;48(1):88-98. doi: 10.1002/hep.22295.
Zotero 插件